2. Cytoskeleton
  3. Myosin

Myosin

Myosin

Related Products

PDF 0.33 MB

Myosins are mechanoenzymes that interact with actin filaments and hydrolyse ATP to generate movement and force. This enables myosins to propel the sliding of actin filaments, to produce tension on actin filaments and to walk along these filaments. As a result, myosins can regulate the structure and dynamics of the actin cytoskeleton and affect the localization and transport of cellular components. The different myosins are grouped into classes on the basis of their motor domains. There are 35 known classes of myosin, and humans have 40 myosin genes that fall into 13 classes (I, II, III, V, VI, VII, IX, X, XV, XVI, XVIII, XIX and XXXV).

Myosins are actin-dependent motors that participate in a diverse range of crucial activities, including muscle contraction, intracellular trafficking, cell division, motility, actin cytoskeletal organisation and cell signaling. Myosin malfunction has been implicated in a variety of disorders including deafness, hypertrophic cardiomyopathy, Usher syndrome, Griscelli syndrome and cancer.

Myosin light chain kinase (MLCK) is an enzyme that activates the myosin light chain to exert its function related to cytoskeleton contraction and tight junction regulation. In most cells, MLCK is a transducer for signalling MLC phosphorylation in response to Ca2+ binding to MLCK-associated calmodulin. MLCK-mediated MLC phosphorylation and actomyosin contractility is important in muscle contraction, cell migration, and endo/exocytic processes, and is recognized for its central role in signalling endothelial cell-cell adhesion and barrier function.

Myosin Related Products (38):

Cat. No. Product Name Effect Purity
  • HY-13813
    Blebbistatin Inhibitor
    Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function. Blebbistatin blocks cell migration[1][2].
  • HY-14233
    Omecamtiv mecarbil Activator 99.79%
    Omecamtiv mecarbil (CK-1827452) is a selective cardiac myosin activator.
  • HY-15417
    ML-7 hydrochloride Inhibitor 99.63%
    ML-7 hydrochloride is a naphthalene sulphonamide derivative, potently inhibits MLCK (IC50=300 nM). ML-7 hydrochloride also inhibits YAP/TAZ.
  • HY-13441
    (-)-Blebbistatin Inhibitor
    (-)-Blebbistatin is a selective inhibitor of the ATPase activity of non-muscle myosin II[1][2].
  • HY-109037
    Mavacamten Modulator
    Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
  • HY-122200
    Phenamacril Inhibitor
    Phenamacril (JS399-19) inhibits activity of myosin I non-competitively with an IC50 of 360 nM through suppression of the ATPase activity, exhibits therefore an antifungal efficacy towards Fusarium species[1].
  • HY-163120
    Myosin-IN-1 Inhibitor
    Myosin-IN-1 (compound F10) is a Myosin inhibitor that specifically targets cardiac myosin. Myosin-IN-1 stabilizes the biochemical and structural closed state of the cardiac myosin motor domain and reduces myocardial force production and calcium sensitivity in vitro. Myosin-IN-1 acts as a negative inotropic agent in isolated Langendroff-perfused rat hearts, reducing stress in isolated myofilaments and left ventricular pressure development. Myosin-IN-1 can be used in heart failure research[1].
  • HY-148516A
    (R)-MPH-220 Inhibitor 98.66%
    (R)-MPH-220 is the R isomer of MPH-220 (HY-148516). MPH-220 is a selective and orally active inhibitor of skeletal muscle myosin-2. MPH-220 enables muscle relaxation. MPH-220 is anti-spastic agent that can be used in the research of spasticity and muscle stiffness[1].
  • HY-139465
    Aficamten Inhibitor 99.87%
    Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM)[1].
  • HY-100932A
    ML-9 Free Base Inhibitor
    ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity[3]. ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively[1]. ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation[3].
  • HY-152206
    JB062 Inhibitor
    JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiac muscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy[1].
  • HY-100948B
    ATM-3507 trihydrochloride Inhibitor
    ATM-3507 trihydrochloride is a potent tropomyosin inhibitor with IC50s from 3.83-6.84 μM in human melanoma cell lines.
  • HY-100984
    HA-100 Inhibitor 99.80%
    HA-100 is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK inhibitor[1][2].
  • HY-P2162
    Kemptamide
    Kemptamide, a 13 amino acid fragment with a sequence corresponding to residues 11-23 of gizzard light chain. Kemptamide is a peptide substrate of myosin light-chain kinase (MLCK)[1].
  • HY-109037S
    Mavacamten-d6 Modulator
    Mavacamten-d6 (MYK461-d6; SAR439152-d6) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
  • HY-120870
    para-Nitroblebbistatin Inhibitor
    para-Nitroblebbistatin is a non-cytotoxic, photostable, fluorescent and specific Myosin II inhibitor, usd in the study of the specific role of myosin II in physiological, developmental, and cell biological studies[1].
  • HY-P3965
    16-38-Thymosin β4 (cattle) Activator 98.14%
    16-38-Thymosin β4 (cattle) is a Ca2+-independent MLCK activator with high affinity[1].
  • HY-152949
    Myosin V-IN-1 Inhibitor
    Myosin V-IN-1 (compound 8) is a potent and selective Myosin V inhibitor, with a Ki of 6 μM. Myosin V-IN-1 shows acute inhibition of myosin V. Myosin V-IN-1 slows the actin-activated myosin V ATPase by specifically inhibiting ADP release from the actomyosin complex[1][2].
  • HY-152190
    JB002 Inhibitor 99.32%
    JB002 is a myosin II inhibitor, with an IC50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy[1].
  • HY-100932
    ML-9 Inhibitor 99.89%
    ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity[3]. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively[1]. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation[3].